Wojciech Figiel

Dr. Wojciech Figiel


Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 July 2022 in Annals of Surgery
Verified
Journal Article
Open access
FAFariba Abbassi
Fariba Abbassi
DGDaniel Gero
Daniel Gero
XMXavier Muller
Xavier Muller
ABAlba Bueno
Alba Bueno
WFWojciech Figiel
Wojciech Figiel
PCPierre-Alain Clavien
Pierre-Alain Clavien
Objective: To define benchmark cutoffs for redo liver transplantation (redo-LT). Background: In the era of organ shortage, redo-LT is frequently discussed in terms of expected poor outcome and wasteful resources. However, there is a lack of benchmark data to reliably evaluate outcomes after redo-LT. Methods: We collected data on redo-LT between January 2010 and December 2018 from 22 high-volume transplant centers. Benchmark cases were defined as recipients with model of end stage liver disease (MELD) score ≤25, absence of portal vein thrombosis, no mechanical ventilation at the time of surgery, receiving a graft from a donor after brain death. Also, high-urgent priority and early redo-LT including those for primary nonfunction (PNF) or hepatic artery thrombosis were excluded. Benchmark cutoffs were derived from the 75th percentile of the medians of all benchmark centers. Results: Of 1110 redo-LT, 373 (34%) cases qualified as benchmark cases. Among these cases, the rate of postoperative complications until discharge was 76%, and increased up to 87% at 1-year, respectively. One-year overall survival rate was excellent with 90%. Benchmark cutoffs included Comprehensive Complication Index CCI® at 1-year of ≤72, and in-hospital and 1-year mortality rates of ≤13% and ≤15%, respectively. In contrast, patients who received a redo-LT for PNF showed worse outcomes with some values dramatically outside the redo-LT benchmarks. Conclusion: This study shows that redo-LT achieves good outcome when looking at benchmark scenarios. However, this figure changes in high-risk redo-LT, as for example in PNF. This analysis objectifies for the first-time results and efforts for redo-LT and can serve as a basis for discussion about the use of scarce resources.

4 August 2023 in Cancers
Verified
Journal Article
Open access
PDF file
ŁMŁukasz Masior
Łukasz Masior
MKMaciej Krasnodębski
Maciej Krasnodębski
MKMikołaj Kuncewicz
Mikołaj Kuncewicz
KKKacper Karaban
Kacper Karaban
IJIgor Jaszczyszyn
Igor Jaszczyszyn
MGMichał Grąt
Michał Grąt
Transarterial chemoembolization (TACE) is used as a bridging treatment in liver transplant candidates with hepatocellular carcinoma (HCC). Alpha-fetoprotein (AFP) is the main tumor marker used for HCC surveillance. The aim of this study was to assess the potential of using the AFP change after the first TACE in the prediction of complete tumor necrosis. The study comprised 101 patients with HCC who underwent liver transplantation (LT) after TACE in the period between January 2011 and December 2020. The ΔAFP was defined as the difference between the AFP value before the first TACE and AFP either before the second TACE or the LT. The receiver operator characteristics (ROC) curves were used to identify an optimal cut-off value. Complete tumor necrosis was found in 26.1% (18 of 69) and 6.3% (2 of 32) of patients with an initial AFP level under and over 100 ng/mL, respectively (p = 0.020). The optimal cut-off value of ΔAFP for the prediction of complete necrosis was a decline of ≥10.2 ng/mL and ≥340.5 ng/mL in the corresponding subgroups. Complete tumor necrosis rates were: 62.5% (5 of 8) in patients with an initial AFP < 100 ng/mL and decline of ≥10.2 ng/mL; 21.3% (13 of 61) in patients with an initial AFP < 100 ng/mL and decline of 100 ng/mL and decline of ≥340.5 ng/mL; and null in 20 patients with an initial AFP > 100 ng/mL and decline of <340.5 ng/mL, respectively (p = 0.003). The simple scoring system, based on the initial AFP and AFP decline after the first treatment, distinguished between a high, intermediate and low probability of complete necrosis, with an area under the ROC curve of 0.699 (95% confidence intervals 0.577 to 0.821, p = 0.001). Combining the initial AFP with its change after the first treatment enables early identification of the efficacy of TACE.

1 June 2016 in Transplantation Proceedings
Verified
Journal Article
Closed access
ŁMŁukasz Masior
Łukasz Masior
MGM. Grąt
M. Grąt
MKMaciej Krasnodębski
Maciej Krasnodębski
WPW. Patkowski
W. Patkowski
WFWojciech Figiel
Wojciech Figiel
MKM. Krawczyk
M. Krawczyk

1 September 2018 in Transplantation Proceedings
Verified
Journal Article
Closed access
GNG. Niewińsk
G. Niewińsk
JRJoanna Raszeja-Wyszomirska
Joanna Raszeja-Wyszomirska
RGRenata Główczyńska
Renata Główczyńska
WFWojciech Figiel
Wojciech Figiel
KZK. Zając
K. Zając
MGM. Grąt
M. Grąt

1 November 2016 in Transplantation Proceedings
Verified
Journal Article
Closed access
BSBeata Sulik-Tyszka
Beata Sulik-Tyszka
WFWojciech Figiel
Wojciech Figiel
MKM. Krawczyk
M. Krawczyk
MWM. Wróblewska
M. Wróblewska

Verified
Journal Article
Open access
PDF file
HZHubert Zywno
Hubert Zywno
WFWojciech Figiel
Wojciech Figiel
MGMichał Grąt
Michał Grąt
SNSławomir D. Nazarewski
Sławomir D. Nazarewski
ZGZbigniew Galazka
Zbigniew Galazka
Jolanta MałyszkoJolanta Małyszko
Jolanta Małyszko
Acute kidney injury (AKI) constitutes a common complication associated with liver or kidney transplantation, which may significantly impact the graft condition and perioperative mortality. Current AKI diagnostic criteria based on serum creatinine (sCr) and urine output alterations are widely utilized in routine clinical practice. However, the diagnostic value of sCr may be limited by various confounding factors, including age, sex, reduced or increased muscle mass, and pre-existing chronic kidney disease (CKD). Furthermore, sCr is rather a late indicator of AKI, as its concentration tends to increase only when the severity of the injury is enough to decrease the estimated glomerular filtration rate (eGFR). Recent expertise highlights the need for novel biomarkers in post-transplantation AKI diagnosis, prediction of event-associated mortality, or evaluation of indications for renal replacement treatment (RRT). Over the last decade, the diagnostic performance of various AKI biomarkers has been assessed, among which some showed the potential to outperform sCr in AKI diagnosis. Identifying susceptible individuals, early diagnosis, and prompt intervention are crucial for successful transplantation, undisturbed graft function in long-term follow-up, and decreased mortality. However, the research on AKI biomarkers in transplantation still needs to be explored. The field lacks consistent results, rigorous study designs, and external validation. Considering the rapidly growing prevalence of CKD and cirrhosis that are associated with the transplantation at their end-stage, as well as the existing knowledge gap, the aim of this article was to provide the most up-to-date review of the studies on novel biomarkers in the diagnosis of post-transplantation AKI.